Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Policy / Regulatory

NMPA Releases 89th Batch of Reference Drugs for GQCE Work

Fineline Cube Jan 10, 2025

The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for...

Policy / Regulatory

China’s NHC Aims for Over 90% Child-Friendly Hospitals by 2030

Fineline Cube Jan 10, 2025

The Department of Maternal and Child Health Care of the National Healthcare Commission (NHC) has...

Company Deals

Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline

Fineline Cube Jan 10, 2025

US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical,...

Company Drug

GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis

Fineline Cube Jan 10, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...

Company Deals

Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong

Fineline Cube Jan 10, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...

Company Deals

Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS

Fineline Cube Jan 9, 2025

Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...

Company Drug

NHSA Revises 2024 NRDL Drug Information Based on Public Feedback

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...

Company

Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities

Fineline Cube Jan 9, 2025

Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...

Company Deals

Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation

Fineline Cube Jan 9, 2025

China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation...

Company Drug

Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer

Fineline Cube Jan 9, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...

Company Drug

HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy

Fineline Cube Jan 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines...

Company Deals

China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia

Fineline Cube Jan 9, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition...

Company Deals

Huahai Pharmaceutical to Transfer Rights to Innovative Antidepressant HHT001 via Public Listing

Fineline Cube Jan 9, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is set to transfer the patent and...

Company Drug

Mabwell’s 9MW2821 Granted Breakthrough Therapy Designation by CDE for Urothelial Carcinoma

Fineline Cube Jan 9, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that the Center for Drug...

Company Drug

Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China

Fineline Cube Jan 9, 2025

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...

Company Deals

Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform

Fineline Cube Jan 9, 2025

US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ:...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/ritonavir Approved in Macau

Fineline Cube Jan 9, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product,...

Company Medical Device

Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment

Fineline Cube Jan 9, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System...

Company Deals

Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology

Fineline Cube Jan 9, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia,...

Company Drug

Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China

Fineline Cube Jan 9, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Posts pagination

1 … 227 228 229 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.